10-Q: Seres Therapeutics Q3 2025: Cash Concerns Amidst Clinical Progress

Seres Therapeutics reports Q3 2025 net income driven by VOWST sale proceeds, but faces substantial doubt about its ability to continue as a going concern beyond Q2 2026 without additional funding.

Summary

• Seres Therapeutics reported a net income from continuing operations of $8.2 million for the three months ended September 30, 2025, and $21.0 million for the nine months ended September 30, 2025, primarily due to gains from the sale of its VOWST business.
• The company incurred a loss from operations of $74.6 million for the nine months ended September 30, 2025.
• Cash and cash equivalents stood at $47.6 million as of September 30, 2025, with an accumulated deficit of $957.1 million.
• Management anticipates funding operations only through the second quarter of 2026 and has identified conditions that raise substantial doubt about the company's ability to continue as a going concern.
• Research and development expenses decreased by $3.8 million to $12.6 million for the three months, and by $14.4 million to $37.4 million for the nine months ended September 30, 2025, primarily due to lower headcount and completion of the SER-155 Phase 1b study.
• General and administrative expenses decreased by $3.2 million to $9.5 million for the three months, and by $9.1 million to $31.6 million for the nine months ended September 30, 2025, also due to lower headcount and cost containment.
• The company completed the sale of its VOWST business to Nestlé Health Science (SPN) in September 2024, receiving cash installment payments of $50 million in January 2025 and $25 million in July 2025, contributing to the gain on sale.
• SER-155, an investigational oral live biotherapeutic, received Breakthrough Therapy designation from the FDA in December 2024 for reducing bacterial bloodstream infections (BSIs) in allo-HSCT patients.
• Phase 1b study results for SER-155 showed a 77% relative risk reduction in bacterial BSIs and a significant reduction in systemic antibiotic exposure compared to placebo.
• A Phase 2 study for SER-155 in allo-HSCT is planned, expected to enroll approximately 248 participants with an interim analysis, but requires additional capital to commence.
• Seres Therapeutics was awarded a CARB-X grant of up to $3.6 million in July 2025 to develop an oral liquid formulation of SER-155 for ICU patients, recognizing $0.4 million in Q3 2025.
• The company implemented cost reduction actions, including a workforce reduction of approximately 25% in September 2025, incurring $1.0 million in restructuring costs.
• Seres regained compliance with Nasdaq's minimum bid price requirement in May 2025 following a 1-for-20 reverse stock split in April 2025.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the explicit 'going concern' warning and limited cash runway, which overshadows positive clinical progress for SER-155 and the non-operational net income from the VOWST sale. The need for significant additional capital by Q2 2026 presents a critical financial challenge.

Positives

• Reported net income from continuing operations of $8.2 million for the three months and $21.0 million for the nine months ended September 30, 2025, largely driven by VOWST sale proceeds.
• Received $75 million in cash installment payments from Nestlé Health Science in January and July 2025 as part of the VOWST business sale.
• SER-155 received Breakthrough Therapy designation from the FDA in December 2024 for reducing bacterial bloodstream infections in allo-HSCT patients, indicating potential for expedited development.
• Phase 1b study results for SER-155 demonstrated a 77% relative risk reduction in bacterial bloodstream infections and a significant reduction in systemic antibiotic exposure.
• Awarded a CARB-X grant of up to $3.6 million in July 2025 to develop an oral liquid formulation of SER-155 for medically vulnerable patient populations.
• Regained compliance with Nasdaq's minimum bid price requirement in May 2025, mitigating immediate delisting concerns.
• Intellectual property rights for SER-155 and SER-147 extend through at least 2043, providing long-term protection for key pipeline assets.

Negatives

• Management has identified conditions and events that raise substantial doubt about the company's ability to continue as a going concern for 12 months from the date of the financial statements' issuance.
• The company anticipates funding its operations only through the second quarter of 2026, necessitating additional capital.
• Incurred a loss from operations of $74.6 million for the nine months ended September 30, 2025, indicating ongoing operational cash burn.
• Implemented cost reduction actions, including a workforce reduction of approximately 25% in September 2025, reflecting financial pressures.
• The planned SER-155 Phase 2 study requires additional capital to begin, potentially delaying its advancement.
• A patent infringement lawsuit was filed against the company and Nestlé by Vedanta Biosciences, Inc. and The University of Tokyo regarding VOWST, which could result in significant legal expenses and liabilities.
• The total amount of future milestone payments from the VOWST transaction and profit sharing payments are subject to various risks and uncertainties, and may not be fully realized or could be less than expected.

Risks

• Need for additional funding to advance product candidates and commercialize, with potential for further cost-reduction measures, program delays, or winding down operations if capital or partnerships are not secured.
• Substantial doubt regarding the ability to continue as a going concern.
• Expectation to incur losses for the foreseeable future and may never achieve or maintain profitability.
• Uncertainty regarding the total amount of Milestone Payments and Profit Sharing Payments from the VOWST Transaction.
• Inability to realize anticipated benefits of the VOWST Transaction and facing new challenges as a smaller, less diversified company.
• Limited operating history making it difficult to evaluate business success and future viability.
• Early stage of development for product candidates, with no assurance of success in building a pipeline or developing marketable drugs.
• Product candidates are based on novel live biotherapeutics, which may face longer or more uncertain regulatory review processes.
• Clinical drug development is risky, lengthy, and expensive, with uncertain outcomes, potentially leading to delays or inability to complete development and commercialization.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent regulatory approvals.
• Disruptions at the FDA and other government agencies could hinder timely development, approval, or commercialization.
• Current and future legislation or regulation may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and may adversely affect prices.
• Reliance on third parties to conduct clinical trials, who may not perform satisfactorily or meet deadlines.
• Even if approved, product candidates may fail to achieve market acceptance by physicians, patients, hospitals, and third-party payors.
• Substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• Inability to adequately protect proprietary technology or obtain and maintain issued patents, leading to direct competition.
• Future success depends on the ability to manage recent CEO transition, retain key executives, and attract, retain, and motivate qualified personnel.
• Recent reverse stock split may not result in the market price per share exceeding or remaining above the $1.00 minimum bid price required by Nasdaq, or maintaining other listing rules.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Competition from biosimilars could materially adversely impact future commercial prospects.
• Failure to obtain marketing approval in international jurisdictions would prevent product candidates from being marketed abroad.
• Product candidates, if approved, will remain subject to significant post-marketing regulatory requirements and oversight.
• Risk of being found to have improperly promoted off-label uses of approved products, leading to significant liability.
• Relationships with customers, physicians, and third-party payors are subject to anti-kickback, fraud and abuse, and other healthcare laws and regulations, exposing the company to sanctions.
• Complex and changing laws and regulations, including ESG practices, expose the company to potential liabilities, increased costs, and adverse effects on reputation and access to capital.
• Ability to use net operating loss carryforwards and research and development credits may be subject to limitations due to ownership changes.

Future Outlook

The company anticipates funding its operations through the second quarter of 2026 and will require additional capital to support ongoing operations and meet obligations. Management plans to seek financing through strategic transactions, including potential business development partnerships, and equity offerings. The SER-155 Phase 2 study is expected to enroll approximately 248 participants with an interim data analysis within twelve months following study initiation, which could inform a single Phase 3 trial for registration. Development of an oral liquid formulation of SER-155 for ICU patients is supported by a CARB-X grant, and IND-enabling activities for SER-147 are ongoing. An investigator-sponsored trial for SER-155 in immune checkpoint related enterocolitis is expected to complete enrollment by end of 2025 with a clinical readout in early 2026.

Management Comments

• "We anticipate that we will fund our operations through the second quarter of 2026."
• "Substantial doubt exists about our ability to continue as a going concern for 12 months from the date these condensed consolidated financial statements are issued."
• "We are actively seeking a business development transaction, which may include a partnership, to provide financial support and who shares our vision to realize the clinical and commercial value of SER-155."
• "We believe that positive results, if achieved, from the Phase 2 study could enable advancement into a single Phase 3 trial to support registration."

Industry Context

Seres Therapeutics operates in the highly competitive and rapidly evolving biotechnology industry, specifically focusing on novel live biotherapeutics. The successful FDA approval of VOWST, though now sold, validated this novel therapeutic approach in the context of infection. The company's focus on SER-155 targets bacterial bloodstream infections and antimicrobial resistance (AMR), which the World Health Organization has declared a top ten global public health threat, indicating a significant unmet medical need. The development of microbiome-based therapies is an emerging field, and regulatory authorities are still gaining experience in evaluating such novel product candidates, which could impact development timelines and costs. The industry also faces increasing scrutiny over drug pricing and reimbursement, as well as evolving data protection and ESG regulations.

Management Changes

Corporate Governance

Legal Proceedings

• On August 20, 2024, Vedanta Biosciences, Inc. and The University of Tokyo filed a patent infringement complaint against Seres Therapeutics, Inc. and Nestlé S.A. (and affiliates) in the U.S. District Court for the District of Delaware. The complaint alleges that the making, sale, and use of VOWST infringes on five U.S. patents. The complaint seeks unspecified damages, fees, expenses, and injunctive relief. Seres believes the complaint is without merit and intends to defend itself vigorously.

Related Party Transactions

• Ongoing Transition Services Agreement (TSA) with NESA (an affiliate of SPN/Nestlé) for manufacturing and administrative services related to the VOWST Business until December 31, 2025, and other services for specified durations.
• Received $2,028 thousand and $11,827 thousand in TSA reimbursement income for the three and nine months ended September 30, 2025, respectively.
• Incurred $736 thousand and $5,952 thousand in manufacturing services expenses and $76 thousand and $3,585 thousand in TSA labor and passthrough expenses for the three and nine months ended September 30, 2025, respectively.
• Billed NESA $1,756 thousand and $13,743 thousand for transition services and received payments of $2,212 thousand and $90,385 thousand (including VOWST installment payments) for the three and nine months ended September 30, 2025, respectively.
• As of September 30, 2025, had $426 thousand in accounts receivable due from SPN and $53 thousand in unbilled receivables.
• Accrued liabilities due to SPN related party totaled $4,450 thousand as of September 30, 2025, including $1,695 thousand for Profit Sharing Payments, $2,150 thousand for MSK Agreement royalties, $222 thousand for VOWST post-marketing safety study, and $383 thousand for 80.1% of Waltham facility lease cost.
• Paid $6,284 thousand and $7,593 thousand to SPN related to the Purchase Agreement during the three and nine months ended September 30, 2025, respectively.
• SPN purchased 714,285 shares of common stock for $15 million at the closing of the VOWST transaction, and has the right to designate a board member as long as it owns at least 10% of outstanding common stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity raises and stock price volatility due to the 'going concern' warning and reliance on external funding. The value of future milestone payments from the VOWST sale is uncertain.
• **Employees**: Experienced a workforce reduction of approximately 25%, leading to potential morale issues and increased workload for remaining staff. Retention bonuses were issued to key personnel to mitigate turnover.
• **Patients**: Potential beneficiaries of SER-155 and SER-147 if clinical development is successful and products are approved, particularly for bacterial bloodstream infections and chronic liver disease. Delays in clinical trials due to funding could impact patient access to these novel therapies.
• **Creditors**: The 'going concern' warning and limited cash runway increase the risk for current and future creditors, potentially impacting the company's ability to secure debt financing on favorable terms.
• **Nestlé Health Science (SPN)**: Continues to be a key partner through the Transition Services Agreement and profit-sharing arrangement, as well as a significant shareholder. The patent infringement lawsuit involving VOWST could impact their commercialization efforts for the product.

Next Steps

• Obtain additional capital and other resources to support further development of SER-155 and the broader portfolio of live biotherapeutic product candidates.
• Initiate the SER-155 Phase 2 study in allo-HSCT patients, pending securing additional capital.
• Continue working with the FDA to finalize the SER-155 Phase 2 study protocol.
• Obtain interim clinical results from the SER-155 Phase 2 study within twelve months following study initiation.
• Engage with the FDA on the design of a Phase 3 study for SER-155 based on Phase 2 results.
• Advance the development of an oral liquid formulation of SER-155 for ICU patients, supported by the CARB-X grant.
• Complete enrollment in the investigator-sponsored trial (IST) evaluating SER-155 in immune checkpoint related enterocolitis by the end of 2025, with a clinical readout expected in early 2026.
• Continue IND-enabling activities for SER-147.
• Evaluate a range of potential deal structures and partnerships to leverage live biotherapeutics expertise and support clinical advancement.

Key Dates

Recommendation

The company's explicit disclosure of 'substantial doubt about its ability to continue as a going concern' and a limited cash runway through Q2 2026 presents an immediate and severe financial risk. While there are positive clinical developments for SER-155 and some non-operational income from the VOWST sale, these are overshadowed by the fundamental liquidity concerns and the urgent need for significant additional capital. A seasoned investor would prioritize capital preservation given the high uncertainty and the potential for further dilution or even bankruptcy if funding is not secured on acceptable terms. The ongoing patent litigation adds another layer of risk. Therefore, a 'sell' recommendation is warranted to mitigate exposure to these significant financial and operational uncertainties.

Keywords

Biotherapeutics, Microbiome, SER-155, Allogeneic Hematopoietic Stem Cell Transplantation, Bacterial Bloodstream Infections, Antimicrobial Resistance, SER-147, Chronic Liver Disease, VOWST, Clinical-stage, Biotechnology, Pharmaceutical, FDA, Intellectual Property, Going Concern, Nasdaq, CARB-X